X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	69.63	55.7	99.22	121.72	81.79	78.71
Short-Term Investments	52.56	46.36	15	-	-	-
Cash & Short-Term Investments	122.19	102.06	114.22	121.72	81.79	78.71
Cash Growth	-9.47%	-10.64%	-6.16%	48.82%	3.91%	-37.62%
Accounts Receivable	0.89	1.07	-	-	-	-
Other Receivables	0.72	0.64	0.56	1.15	0.75	0.92
Receivables	1.61	1.71	0.56	1.15	0.75	0.92
Inventory	4.08	2.82	-	-	-	-
Prepaid Expenses	4.7	5.59	7.05	5.52	5.34	3.42
Restricted Cash	0.22	-	0.25	0.29	-	0.26
Total Current Assets	132.81	112.18	122.08	128.68	87.88	83.31
Property, Plant & Equipment	1.99	4.84	6.4	8.33	10.22	9.2
Goodwill	17.35	17.35	17.35	17.35	17.35	27.11
Other Intangible Assets	9.44	10	-	-	-	-
Other Long-Term Assets	1.97	2.08	1.44	1.23	1.72	3.26
Total Assets	163.56	146.45	147.26	155.59	117.18	122.87
Accounts Payable	5.05	8.62	8.95	7.78	4.28	3.14
Accrued Expenses	16.44	23.01	12.82	11.44	7.85	8.02
Current Portion of Long-Term Debt	-	-	-	1.32	0.8	-
Current Portion of Leases	1.2	1.25	1.1	1.2	1.08	0.79
Other Current Liabilities	0.22	-	-	0.59	0.03	-
Total Current Liabilities	23.51	32.88	22.86	22.32	14.02	11.95
Long-Term Debt	76.06	75.43	54.57	32.3	33.14	33.18
Long-Term Leases	0.1	1.41	2.61	3.6	4.78	4.48
Other Long-Term Liabilities	1.48	14.59	16.12	23.3	0.83	0.46
Total Liabilities	101.94	124.3	96.16	81.54	52.76	50.07
Common Stock	0.03	0.17	0.17	0.12	0.03	0.02
Additional Paid-In Capital	632.34	537.46	528.96	450.79	347.37	267.08
Retained Earnings	-570.63	-515.36	-477.91	-376.74	-282.87	-194.18
Comprehensive Income & Other	-0.12	-0.12	-0.12	-0.12	-0.12	-0.12
Total Common Equity	61.62	22.15	51.1	74.05	64.41	72.8
Shareholders' Equity	61.62	22.15	51.1	74.05	64.41	72.8
Total Liabilities & Equity	163.56	146.45	147.26	155.59	117.18	122.87
Total Debt	77.36	78.09	58.28	38.42	39.79	38.45
Net Cash (Debt)	44.84	23.97	55.94	83.3	42	40.26
Net Cash Growth	-21.02%	-57.14%	-32.85%	98.32%	4.33%	-61.02%
Net Cash Per Share	2.78	3.58	9.44	39.34	48.94	60.16
Filing Date Shares Outstanding	87.44	5.79	5.6	4.07	1.03	0.58
Total Common Shares Outstanding	25.15	5.7	5.58	4.06	0.94	0.54
Working Capital	109.3	79.3	99.21	106.35	73.86	71.36
Book Value Per Share	2.45	3.89	9.16	18.26	68.70	133.94
Tangible Book Value	34.83	-5.2	33.75	56.7	47.06	45.69
Tangible Book Value Per Share	1.39	-0.91	6.05	13.98	50.19	84.06
Machinery	-	2.43	2.11	2.08	1.98	1.25
Leasehold Improvements	-	0.23	0.23	0.23	0.23	0.23

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q